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ties in Asia. CDAD is estimated to cost 
the healthcare system in the United 
States $3.2 billion annually (8). With 
longer hospitalization for persons af-
ter they test positive for CDT, as seen 
in our study, rising CDAD rates could 
increase hospital occupancy and result 
in excess healthcare expenditures.
CDAD in Asia is an emerging 
challenge that needs to be recognized. 
Its control will ultimately depend on 
priority being given to epidemiologic 
surveillance, infection control, and 
stewardship of antimicrobial agents.
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West Nile Virus 
in Golden Eagles, 
Spain, 2007 
To the Editor: Although West 
Nile virus (WNV) has not been isolat-
ed in Spain, several recent studies pro-
vide evidence for its circulation in this 
country (1–5). We report isolation of 
WNV in Spain from 2 golden eagles 
(Aquila chrysaetos). 
A captive-bred 2-year-old male 
golden eagle (GE-1) was released 
into the wild in central Spain. The 
bird’s location was monitored daily 
by telemetry, and it remained within 
a radius of 100 km from its original 
release point. On September 15, 2007 
(1 month after release), it was found 
moribund and was moved to a reha-
bilitation and captive breeding center 
for endangered raptors. Upon admis-
sion, the bird was in fair condition 
but debilitated and aggressive. It then 
became increasingly disorientated, 
showed a head tilt, and died 5 days 
after admission, despite intensive 
supportive care and treatment for sec-
ondary infections.
Eleven days after admission of 
GE-1, an adult male golden eagle 
(GE-2) and an adult female Bonelli’s 
eagle (Hieraaetus fasciatus [BE-1]) 
living in pairs (with a golden eagle 
and a Bonelli’s eagle, respectively) in 
enclosures were found disorientated, 
debilitated, and with impaired vision. 
Both birds where placed in isolation 
and received intensive supportive 
care; they slowly recovered. The re-
spective pair of each bird (GE-3 and 
BE-2, respectively) remained asymp-
tomatic. A magpie (MP-1) that had 
entered the golden eagle enclosure 5 
days before admission of GE-1 was 
also placed in isolation, but remained 
healthy. After necropsy of GE-1, 
tissue samples (brain, kidney, and 
spleen) from this bird and oropha-
ryngeal swabs from GE-2, BE-1, and 
MP-1 (obtained at day 11 after ad-
mission of GE-1) were subjected to 
virologic analysis.
Avian inﬂ   uenza and Newcastle 
disease were excluded by reverse 
transcription–PCR (RT-PCR) (6,7) of 
oropharyngeal and cloacal swabs from 
GE-1, GE-2, BE-1, and MP-1. Real-
time RT-PCR speciﬁ   c for WNV (8) 
was conducted with brain, kidney, and 
spleen tissue homogenates from GE-1 
and oropharyngeal swabs from GE-2, 
BE-1, and MP-1. All samples except 
that from MP-1 yielded speciﬁ  c WNV 
genome ampliﬁ  cation products, which 
were conﬁ  rmed  after  ampliﬁ  cation 
and sequencing by using a previously 
described method (9).
Serum samples from clinically 
affected eagles (GE-1, GE-2, and 
BE-1), the magpie (MP-1), and the 
healthy Bonelli’s eagle (BE-2) con-
tained WNV-neutralizing antibodies 
detected by a virus neutralization test 
performed as described (4,5). A serum 
sample from GE-3 (asymptomatic) 
remained negative up to 74 days af-
ter admission of GE-1. Speciﬁ  city of 
the neutralization test was assessed LETTERS
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by titration in parallel against a sec-
ond, cross-reacting ﬂ  avivirus (Usutu 
virus). Results showed that the high-
est titers were always obtained against 
homologous virus (WNV).
Virus isolation was conducted by 
placing  ﬁ  lter-sterilized,  clariﬁ  ed  tis-
sue homogenates (brain, kidney and 
spleen) from GE-1 and oropharyngeal 
swab eluate from GE-2 onto mono-
layers of BSR (baby hamster kidney) 
cells and Vero cells. The remaining 2 
samples (oropharyngeal swabs from 
BE-1 and MP-1) were negative for vi-
rus. Isolates were identiﬁ  ed by using 
real-time and conventional RT-PCR 
(8,9). WNV-speciﬁ  c cDNAs from the 
nonstructural protein 5–coding region 
of the genome (171 nt) were ampli-
ﬁ  ed by RT-PCR (9) from brain tissue 
of GE-1 (sample GE-1b), oropharyn-
geal swab of BE-1 (sample BE-1o), 
and ﬁ  rst-passage infection supernatant 
of oropharyngeal swab from GE-2 
(sample GE-2o). These samples were 
subjected to molecular analysis. Nu-
cleotide sequences from the 3 samples 
were identical, except at 1 nt position 
in BE-1o (GenBank accession nos. 
EU486169 for GE-1b, EU486170 
for GE-2o, and EU486171 for BE-
1o). Phylogenetic analysis matched 
these isolates most closely with recent 
western Mediterranean WNV isolates 
within lineage 1a (Figure).
WNV was detected in 3 eagles of 
2 species. The birds with the index and 
secondary cases had no direct contact. 
Transmission could have occurred 
through mosquito bites. The 2-year-
old golden eagle died as a result of in-
fection, and the 2 remaining infected 
eagles recovered. The 3 ill birds were 
potentially more susceptible because 
of stress (GE-1) or age (GE-2 and BE-1 
were older birds). Serologic analysis 
detected WNV-speciﬁ  c antibodies in 
the affected birds and some contacts. 
Nucleotide sequence analysis showed 
high genetic identity among these new 
isolates, which cluster within lineage 
1a of WNV. 
Although information on WNV in 
Spain is scarce, its detection and rela-
tionship to the death of a raptor in the 
wild are of concern because many spe-
cies of eagles, including the Spanish 
imperial eagle (A. adalberti), are en-
dangered species. We recently found 
evidence of WNV infection in several 
Spanish imperial eagles sampled dur-
ing 2001–2005 (5). Studies are ongo-
ing to further characterize genetic and 
biologic properties of the new WNV 
isolates described to identify their ge-
netic relationships with other WNV 
strains and to clarify the epidemiology 
of WNV in the study region.
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Figure. Phylogenetic tree of 18 partial nonstructural protein 5 West Nile virus nucleotide 
sequences (171 nt for each isolate, except 126 nt available for the Portugal/04 isolate) 
constructed with MEGA version 4 software (www.megasoftware.net). The optimal tree was 
inferred by using the neighbor-joining method. The percentage of successful bootstrap 
replicates (N = 1,000) is indicated at nodes. Evolutionary distances were computed with the 
Kimura 2-parameter method (with gamma correction). All positions containing alignment 
gaps and missing data were eliminated only in pairwise sequence comparisons. Branch 
lengths are proportional to the number of nucleotide changes (genetic distances). Scale 
bar shows number of base substitutions per site. Isolates sequenced in this study are 
indicated by solid circles. GenBank accession nos. are as follows: France/00 (AY268132), 
Morocco/03 (AY701413), Italy/98 (AF404757), France 405/04 (DQ786572), Portugal/04 
(AJ965630), Israel/98 (AF481864), New York/99 (DQ211652), Egypt/51 (AF260968), Kunjin 
(D00246), Uganda/37 (M12294), Hungary/04 (DQ116961), Rabensburg (AY765264), 
India/80 (DQ256376), Russia/98 (AY277251), and Usutu virus (NC_006551) (outgroup).
Lineage 1
Clade 1a
Clade 1b
Lineage 2
Lineage 3
Lineage 5
Lineage 4LETTERS
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008  1491 
Real, Spain (E. Perez-Ramirez, U. Höﬂ  e)
DOI: 10.3201/eid1409.080190
References
  1.   Boﬁ  ll D, Domingo C, Cardeñoso N, Zara-
goza J, de Ory F, Minguell S, et al. Human 
West Nile virus infection, Catalonia, Spain. 
Emerg Infect Dis. 2006;12:1163–4.
    2.   Kaptoul D, Viladrich PF, Domingo C, 
Niubó J, Martínez-Yélamos S, de Ory F, 
et al. West Nile virus in Spain: reports 
of the ﬁ   rst diagnosed case (in Spain) 
in a human with aseptic meningitis. 
Scand J Infect Dis. 2007;39:70–93. DOI: 
10.1080/00365540600740553
  3.   Figuerola J, Soriguer R, Rojo G, Gómez-
Tejedor C, Jiménez-Clavero MA. Sero-
conversion in wild birds and local circu-
lation of West Nile virus, Spain. Emerg 
Infect Dis. 2007;13:1915–7.
  4.   Figuerola J, Jiménez-Clavero MA, Rojo 
G, Gómez-Tejedor C, Soriguer R. Preva-
lence of West Nile virus neutralizing an-
tibodies in colonial aquatic birds in south-
ern Spain. Avian Pathol. 2007;36:209–12. 
DOI: 10.1080/03079450701332329
  5.   Höﬂ  e U, Blanco JM, Crespo E, Naranjo 
V, Jiménez-Clavero MA, Sanchez A, et 
al. West Nile virus in the endangered 
Spanish imperial eagle. Vet Micro-
biol. 2008;129:171–8. DOI: 10.1016/j.
vetmic.2007.11.006
  6.   Ward CL, Dempsey MH, Ring CJ, Kemp-
son RE, Zhang L, Gor D, et al. Design 
and performance testing of quantitative 
real time PCR assays for inﬂ  uenza A and 
B viral load measurement. J Clin Virol. 
2004;29:179–88. DOI: 10.1016/S1386-
6532(03)00122-7
  7.   Creelan JL, Graham DA, McCullough SJ. 
Detection and differentiation of pathoge-
nicity of avian paramyxovirus serotype 
1 from ﬁ  eld cases using one-step reverse 
transcriptase polymerase chain reac-
tion. Avian Pathol. 2002;31:493–9. DOI: 
10.1080/0307945021000005860
  8.   Jiménez-Clavero  MA,  Agüero  M,  Rojo 
G, Gómez-Tejedor C. A new ﬂ  uorogenic 
real-time RT-PCR assay for detection of 
lineage 1 and lineage 2 West Nile viruses. 
J Vet Diagn Invest. 2006;18:459–62.
  9.   Scaramozzino N, Crance JM, Jouan A, De-
Briel DA, Stoll F, Garin D. Comparison of 
ﬂ  avivirus universal primer pairs and devel-
opment of a rapid, highly sensitive hemin-
ested reverse transcription-PCR assay for 
detection of ﬂ  aviviruses targeted to a con-
served region of the NS5 gene sequences. 
J Clin Microbiol. 2001;39:1922–7. DOI: 
10.1128/JCM.39.5.1922-1927.2001
Address for correspondence: Ursula 
Höﬂ   e, Instituto de Investigación en 
Recursos Cinegéticos, Consejo Superior de 
Investigaciones Cientiﬁ   cas, Universidad de 
Castilla–La Mancha, Junta de Comunidades de 
Castilla–La Mancha, Ciudad Real, Spain; email: 
ursula.hoﬂ  e@uclm.es
Merkel Cell 
Polyomavirus 
and Merkel Cell 
Carcinoma, France
To the Editor: Merkel cell carci-
noma (MCC) is a primary cutaneous 
neuroendocrine tumor. This aggressive 
skin cancer is uncommon but increas-
ing in frequency. During 1986–2001, 
incidence rate tripled; average annual 
increase was 8% (1). MCC shares epi-
demiologic features with Kaposi sarco-
ma, a malignant tumor associated with 
human herpesvirus 8 infection (2). In 
particular, MCC affects predominant-
ly immunocompromised patients such 
as organ transplant recipients (3,4), 
patients with B-cell lymphoid tumors 
(5), and patients with AIDS (6). This 
similarity between MCC and Kaposi 
sarcoma may support the hypothesis 
of an infectious origin of MCC.
A new polyomavirus, provision-
ally named Merkel cell polyomavirus 
(MCPyV), has been recently identi-
ﬁ  ed in tumor tissue from patients with 
MCC. Furthermore, clonal integration 
of viral DNA within the tumor genome 
was observed in most of the cases (7). 
To assess the implication of MCPyV in 
MCC, we tested tumor biopsy samples 
collected from 9 patients with MCC. 
Patient median age was 65 years, and 
2 patients were immunocompromised 
(patient 1 had a lymphoma, which 
was treated with rituximab; patient 7 
had psoriatic rheumatism, which was 
treated with corticosteroids and meth-
otrexate). As controls, biopsy samples 
from 15 patients with diverse prolifer-
ative or inﬂ  ammatory skin or mucosa 
lesions were tested (Table).
DNA was extracted from fresh 
tissue samples by using the QIAamp 
DNA Mini Kit (QIAGEN, Courta-
boeuf, France) according to the manu-
facturer’s instructions. Parafﬁ  n  was 
removed from previously formalde-
hyde-ﬁ  xed, parafﬁ  n-embedded biopsy 
samples with xylene, and the samples 
were rehydrated with decreasing con-
centrations of ethanol. The extracts 
were tested for MCPyV DNA by 
PCR using 3 sets of primers initially 
described by Feng et al. (7) to target 
the predicted T-antigen (LT1 and LT3 
primer pairs) and the viral capsid (VP1 
primer pair) coding regions. Extracted 
DNA (5 μL) was added to 45 μL of the 
reaction mixture, which contained 5 μL 
10× PCR buffer, 10 μL 5× Q-solution 
(QIAGEN),  2.5 mmol/L MgCl2, 200 
μmol/L each dNTP, 2.5 units Taq DNA 
polymerase (QIAGEN), and 15 pmol 
of each primer. Touchdown PCR con-
ditions were as follows: 95°C for 5 min 
followed by 35 cycles of denaturation 
at 95°C for 30 s; annealing at 61°C (10 
cycles), 59°C (10 cycles), and 57°C 
(15 cycles) for 30 s; extension at 72°C 
for 1 min; and a ﬁ  nal extension step at 
72°C for 10 min. Ampliﬁ  cation prod-
ucts were subjected to electrophoresis 
in a 2% agarose, 1× Tris-borate-EDTA 
gel stained with ethidium bromide and 
examined under UV light. The sizes of 
the fragments ampliﬁ  ed with the LT1, 
LT3, and VP1 primers pairs were 439, 
308, and 351 bp, respectively. A nega-
tive control was included in each ex-
periment; positive samples were con-
ﬁ  rmed by analyzing a second stored 
sample aliquot, and the ampliﬁ  ed 
fragments were sequenced by using 
the same primers used for the ampliﬁ  -
cation. The sequences were submitted 
to GenBank under accession numbers 
AM992895–AM992906. Total DNA 
level in sample extracts was measured 
by using the LightCycler control DNA 
kit targeting the β-globin gene (Roche 